Medical Use
Asparlas is an enzyme that specifically targets asparagine, used as part of a multi-drug chemotherapy regimen to treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years.
Recommended Dosage: Administer Asparlas at a dose of 2,500 units/m² intravenously, no more frequently than once every 3 weeks (21 days).
Premedication: To minimize the risk and severity of infusion and hypersensitivity reactions, premedicate patients 30 to 60 minutes before administering Calaspargase pegol-mknl with acetaminophen, an H-1 receptor blocker (like diphenhydramine), and an H-2 receptor blocker (such as famotidine).
Warning & Precautions
Grade 3/4 Hypersensitivity Reactions: Calaspargase injection can cause severe hypersensitivity reactions, including anaphylaxis. Other asparaginases have been associated with symptoms such as lip and eye swelling, angioedema, decreased blood pressure, bronchospasm, erythema, dyspnea, pruritus, and rash.
Pancreatitis: Asparlas can cause pancreatitis, which can be fatal if untreated. Patients should be informed about the signs and symptoms of pancreatitis. Regularly assess serum amylase or lipase levels to detect early signs of pancreatic inflammation. Discontinue therapy if pancreatitis is suspected and do not resume if confirmed.
Thrombotic Events: Serious thrombotic events, including sagittal sinus thrombosis, may occur with Calaspargase pegol-mknl treatment. Discontinue therapy in patients who experience serious thrombotic events.
Hemorrhage: Hemorrhage associated with increased partial thromboplastin time (PTT), increased prothrombin time (PT), and hypofibrinogenemia may occur in patients receiving Asparlas. Monitor patients with signs of hemorrhage using coagulation parameters such as PTT, PT, and fibrinogen levels.
Liver Function and Hepatotoxicity: Abnormal liver function and hepatotoxicity, including reduced serum albumin and elevated transaminase, bilirubin (direct/indirect), and plasma fibrinogen levels, can occur. Monitor bilirubin and transaminases weekly during treatment cycles and for six weeks after the final dose of Calaspargase pegol-mknl.
Fetal Harm: Calaspargase pegol-mknl can cause fetal harm if administered to pregnant women. Pregnancy testing is required for females of reproductive age before starting therapy. Women should avoid breastfeeding during treatment and for three months after the final dose due to potential side effects in the breastfed child.
Documentation Availability
Documents required to import ASPARLAS to India?
ASPARLAS (Calaspargase pegol-mknl) injections can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing ASPARLAS (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
Who manufactures Asparlas®?
Asparlas® is manufactured by Servier Pharmaceuticals LLC.
Is Asparlas® FDA approved?
Yes, Asparlas® was approved by the FDA on December 20, 2018.
What is the dosage and form of Asparlas®?
Asparlas® is available as an injection: 3,750 units/5 mL (750 units/mL) clear, colorless solution in a single-dose vial for intravenous use.
What are the most common side effects of Asparlas®?
Common side effects include increased bilirubin, elevated transaminase levels, pancreatitis, and abnormal clotting studies.
How much does Asparlas® cost in India?
The cost of Asparlas® in India is reasonable. For authentic procurement, you can reach out to Rx4u team.
What are the storage conditions for Asparlas®?
Store Asparlas® in its original carton at 2-8°C (36-46°F) to protect it from light. Do not shake or freeze the product. Unopened vials can be stored at room temperature (15-25°C or 59-77°F) for up to 48 hours.
Is it safe to buy Asparlas® online in India?
Yes, you can safely purchase Asparlas® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
